AstraZeneca Spikes on Brilinta Approval Rumor, Continues to Rise Following FDA Confirmation

by Louis Bedigian, Benzinga Staff Writer

July 20, 2011 5:11 PM | 21 seconds read | Make a Comment

AstraZeneca

AZN

spiked 1% this afternoon

that Brilinta has received FDA approval. Benzinga then spoke with AstraZeneca, which said it

, but expected to soon. Moments later, the company announced that the FDA had

its anti-clotting drug. AstraZeneca has continued to rise in aftermarket trading. At press time, the stock was up more than 3%.

Posted In: Long Ideas Short Ideas Rumors FDA Trading Ideas AstraZeneca Food and Drug Administration Health Care Pharmaceuticals

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.